Still with no head-to-head clinic trial on the matter, we now have a large retrospective VA study of 5779 men with metastatic castrate-resistant prostate cancer reporting a near identical mean restricted survival for those receiving first-line enzalutamide versus abiraterone though the former eeked out a 0.9 month advantage at 4 years. | La, JAMA Netw Open 2024
